Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate.

CONCLUSION: In tofacitinib users, HZ occurred at a rate of approximately 4% per year and was further doubled with GC exposure. Concomitant MTX did not confer additional risk. Zoster vaccination may decrease risk. This article is protected by copyright. All rights reserved. PMID: 30295428 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30295428?dopt=Abstract

Source: Herpes - October 8, 2018 Category: Infectious Diseases Authors: Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, Winthrop K Tags: Arthritis Care Res (Hoboken) Source Type: research